Text Size

Studying Biomarkers in Samples From Young Patients With Rhabdoid Tumors

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01544569
First received: February 29, 2012
Last updated: March 7, 2012
Last verified: March 2012
History of Changes
  Purpose

RATIONALE: Studying samples of tissue from patients with rhabdoid tumors in the laboratory may help doctor learn more about changes that occur in DNA and identify genes related to cancer.

PURPOSE: This research trial studies biomarkers in samples from young patients with rhabdoid tumors.


Condition Intervention
Kidney Cancer
 Genetic: DNA analysis
Genetic: fluorescence in situ hybridization
Genetic: gene expression analysis
Genetic: gene mapping
Genetic: microarray analysis
Genetic: polymerase chain reaction
Genetic: protein expression analysis
Other: laboratory biomarker analysis
Other: medical chart review

Study Type: Observational
Official Title: Endogenous DNA Transposition in Rhabdoid Tumors

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Expression and function of PGBD5 in rhabdoid tumors [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: March 2012
Estimated Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • To investigate the expression and function of PGBD5 in 50 primary rhabdoid tumors.

OUTLINE: Freshly frozen rhabdoid tumors will be studied using fluorescence in situ hybridization (FISH) and polymerase chain reaction (PCR) to establish the genomic location of PGBD5. Protein expression in rhabdoid tumor tissue microarrays is also analyzed.

  Eligibility

Ages Eligible for Study:   up to 1 Year
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Freshly frozen rhabdoid tumors from either renal or extra-renal sites from children younger than 2 years of age
  • Clinical patient information (age, gender, comorbidities, tumor stage, size, pathology, therapy, outcome) available

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01544569

Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Investigators
Principal Investigator: Elizabeth A. Mullen, MD Dana-Farber Cancer Institute
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Peter C. Adamson, Children's Oncology Group - Group Chair Office
ClinicalTrials.gov Identifier: NCT01544569     History of Changes
Other Study ID Numbers: CDR0000727229, COG-AREN12B3
Study First Received: February 29, 2012
Last Updated: March 7, 2012
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
rhabdoid tumor of the kidney

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Kidney Neoplasms
Rhabdoid Tumor
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
 Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Neoplasms, Complex and Mixed

ClinicalTrials.gov processed this record on May 21, 2013